JP2005519590A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005519590A5 JP2005519590A5 JP2003556018A JP2003556018A JP2005519590A5 JP 2005519590 A5 JP2005519590 A5 JP 2005519590A5 JP 2003556018 A JP2003556018 A JP 2003556018A JP 2003556018 A JP2003556018 A JP 2003556018A JP 2005519590 A5 JP2005519590 A5 JP 2005519590A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- polypeptide
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 36
- 229920001184 polypeptide Polymers 0.000 claims 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 102000004196 processed proteins & peptides Human genes 0.000 claims 25
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 7
- 239000000523 sample Substances 0.000 claims 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 239000000556 agonist Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 5
- 230000004936 stimulating effect Effects 0.000 claims 5
- 102100037850 Interferon gamma Human genes 0.000 claims 4
- 108010074328 Interferon-gamma Proteins 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 230000006052 T cell proliferation Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 206010036105 Polyneuropathy Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 239000013068 control sample Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000007824 polyneuropathy Effects 0.000 claims 2
- 230000009257 reactivity Effects 0.000 claims 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010015218 Erythema multiforme Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 108010068370 Glutens Proteins 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000037319 Hepatitis infectious Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 201000005505 Measles Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000012287 Prolapse Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 208000004732 Systemic Vasculitis Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000027207 Whipple disease Diseases 0.000 claims 1
- 238000001467 acupuncture Methods 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000019748 bullous skin disease Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 230000009918 complex formation Effects 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims 1
- 235000021312 gluten Nutrition 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 201000007192 granulomatous hepatitis Diseases 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 208000024557 hepatobiliary disease Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000013643 idiopathic inflammatory myopathy Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2001/027099 WO2002024888A2 (en) | 2000-09-01 | 2001-08-29 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US10/136,574 US7419799B2 (en) | 2001-08-29 | 2002-04-29 | Compositions and methods for the treatment of immune related diseases |
| PCT/US2002/024252 WO2003055440A2 (en) | 2001-08-29 | 2002-07-30 | Compositions and methods for the treatement of immune related diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005519590A JP2005519590A (ja) | 2005-07-07 |
| JP2005519590A5 true JP2005519590A5 (enExample) | 2006-01-05 |
Family
ID=40481851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003556018A Pending JP2005519590A (ja) | 2001-08-29 | 2002-07-30 | 免疫関連疾患の治療のための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7419799B2 (enExample) |
| EP (1) | EP1472273A4 (enExample) |
| JP (1) | JP2005519590A (enExample) |
| KR (1) | KR20040031031A (enExample) |
| AU (2) | AU2002365246A1 (enExample) |
| CA (1) | CA2458751A1 (enExample) |
| MX (1) | MXPA04001986A (enExample) |
| NZ (1) | NZ531311A (enExample) |
| WO (1) | WO2003055440A2 (enExample) |
| ZA (1) | ZA200401536B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1252333A4 (en) * | 2000-01-25 | 2005-01-05 | Nuvelo Inc | METHODS AND SUBSTANCES RELATING TO CD84-TYPE POLYPEPTIDES AND POLYNUCLEOTIDES |
| WO2002077173A2 (en) * | 2001-03-22 | 2002-10-03 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel immunoglobulin superfamily member, apex4, and variants and splice variants thereof |
| US7847067B2 (en) * | 2006-08-28 | 2010-12-07 | ARCA Biopharma | Antibodies to NTB-A |
| KR100975116B1 (ko) * | 2007-12-07 | 2010-08-11 | 이영조 | 가정용 음식물 쓰레기 처리장치의 미생물 공급장치 |
| CN107880126B (zh) | 2012-12-21 | 2021-03-30 | 西雅图基因公司 | 抗ntb-a抗体及相关组合物和方法 |
| WO2014171721A1 (ko) * | 2013-04-16 | 2014-10-23 | 가톨릭대학교 산학협력단 | 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도 |
| KR101625112B1 (ko) | 2013-04-16 | 2016-05-27 | 가톨릭대학교 산학협력단 | 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도 |
| EP3091999B2 (en) | 2014-01-09 | 2025-05-07 | Hadasit Medical Research Services and Development Ltd. | Improved cell compositions and methods for cancer therapy |
| WO2019155474A1 (en) * | 2018-02-12 | 2019-08-15 | Hadasit Medical Research Services & Development Ltd. | Modulation of slamf6 splice variants for cancer therapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| EP1252333A4 (en) * | 2000-01-25 | 2005-01-05 | Nuvelo Inc | METHODS AND SUBSTANCES RELATING TO CD84-TYPE POLYPEPTIDES AND POLYNUCLEOTIDES |
| US7029677B2 (en) * | 2000-01-25 | 2006-04-18 | Nuvelo, Inc. | Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells |
| US20040034194A1 (en) * | 2001-04-11 | 2004-02-19 | Pankaj Agarwal | Novel compounds |
| EP1223218A1 (en) * | 2000-11-03 | 2002-07-17 | Millennium Pharmaceuticals, Inc. | CD2000 and CD2001 molecules and uses thereof |
| AU2002257088A1 (en) * | 2001-03-12 | 2002-09-24 | Incyte Genomics, Inc. | Immunoglobulin superfamily proteins |
| WO2002077173A2 (en) * | 2001-03-22 | 2002-10-03 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel immunoglobulin superfamily member, apex4, and variants and splice variants thereof |
| AU2002325333B2 (en) * | 2001-07-19 | 2008-04-03 | Innate Pharma | NTB-A, a surface molecule involved in natural killer cells activity |
-
2001
- 2001-08-29 MX MXPA04001986A patent/MXPA04001986A/es unknown
-
2002
- 2002-04-29 US US10/136,574 patent/US7419799B2/en not_active Expired - Lifetime
- 2002-07-30 JP JP2003556018A patent/JP2005519590A/ja active Pending
- 2002-07-30 KR KR10-2004-7003104A patent/KR20040031031A/ko not_active Ceased
- 2002-07-30 EP EP02805924A patent/EP1472273A4/en not_active Withdrawn
- 2002-07-30 NZ NZ531311A patent/NZ531311A/en not_active IP Right Cessation
- 2002-07-30 CA CA002458751A patent/CA2458751A1/en not_active Abandoned
- 2002-07-30 WO PCT/US2002/024252 patent/WO2003055440A2/en not_active Ceased
- 2002-07-30 AU AU2002365246A patent/AU2002365246A1/en not_active Abandoned
-
2004
- 2004-02-25 ZA ZA2004/01536A patent/ZA200401536B/en unknown
-
2008
- 2008-07-29 US US12/182,090 patent/US20090017014A1/en not_active Abandoned
-
2009
- 2009-02-17 AU AU2009200614A patent/AU2009200614A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005535290A5 (enExample) | ||
| JP2006516094A5 (enExample) | ||
| JP2010162017A5 (enExample) | ||
| RU2693084C2 (ru) | Антитела, направленные против интерлейкина-33 (il-33) | |
| Watanabe et al. | Leptin enhances cytokine/chemokine production by normal lung fibroblasts by binding to leptin receptor | |
| JP2010187677A5 (enExample) | ||
| JP2007515942A5 (enExample) | ||
| Liang et al. | Pathogenic profiles and molecular signatures of antinuclear autoantibodies rescued from NZM2410 lupus mice | |
| JP2009278998A (ja) | チロトロフィン(tsh)受容体の抗原決定領域、その使用およびその抗体 | |
| JP2006523682A5 (enExample) | ||
| JP2006510619A (ja) | 抗炎症剤としてのhmgb断片の使用 | |
| CN104159919A (zh) | 使用抗干扰素γ抗体的治疗方法 | |
| JP2005519590A5 (enExample) | ||
| MXPA05012497A (es) | Composiciones y metodos para el tratamiento del sindrome respiratorio agudo severo (sars). | |
| JP2021525236A (ja) | 抗il12/il23抗体でループスを治療する安全かつ有効な方法 | |
| CN101896192A (zh) | 一种通过去除或灭活巨噬细胞抑制因子-1而治疗恶病质的方法 | |
| EP3157563A1 (en) | Compositions and methods for safe and effective immunotherapy | |
| JP2006521082A5 (enExample) | ||
| EP2838559B1 (en) | Combination therapy of anti-mif antibodies and glucocorticoids | |
| CN106573968B (zh) | 糖蛋白激素受体突变 | |
| WO2024168965A1 (zh) | 人IL-1R1和人IL-1RAcP多肽片段组合的同源二聚体蛋白质与用途 | |
| Brigatte et al. | Tolerance to the antinociceptive effect of Crotalus durissus terrificus snake venom in mice is mediated by pharmacodynamic mechanisms | |
| WO2025113203A1 (zh) | 抗il-31的抗体及其用途 | |
| JP2006515748A5 (enExample) | ||
| US20250326795A1 (en) | Use of d-enantiomeric peptide ligands of monomeric tau for the therapy of various tauopathies |